Therapure Biopharma Inc. to pave the way for made-in-Canada medicine by
delivering new therapeutic protein production services
TORONTO, Sept. 22 /CNW/ - Today marked the launch of Therapure Biopharma
Inc., a new, first-of-its-kind Canadian biopharmaceutical company that
specializes in developing, manufacturing, purifying, and packaging biological
protein therapeutics. Coinciding with National Biotechnology Week, the
introduction of Therapure Biopharma signifies new opportunities for Canadian
biotechnology companies seeking to bring their products to the global market
and ultimately means better access to better medicine for Canadians.
"Despite the fact that biological protein therapeutics are seen as the
future of medicine around the world and represent one-third of all drugs today
- they are still not well understood by the average Canadian," said Thomas
Wellner, President & CEO of Therapure Biopharma Inc. "Therapure Biopharma is
paving the way for Canadian innovators to continue developing protein-based
therapies that make a difference in the lives of those affected by conditions
like rheumatoid arthritis, Crohn's Disease, Lupus, asthma, and cancer."
Biological proteins can have higher efficacy and fewer side effects than
other pharmaceutical products, as they can be specifically targeted to address
the cause of disease, rather than the treatment of its symptoms.
Arguably one of the first and most significant therapies derived from
biological proteins was insulin, discovered in Ontario by now famous Canadian
scientists Fredrick Banting and Charles Best at the University of Toronto in
1921. Dr. Banting and Dr. Best were able to isolate insulin from the inside of
an animal pancreas. Today, insulin is considered one of the most
groundbreaking achievements in the history of medicine.
The process of manufacturing and regulating production of protein-based
therapeutics is complex and Canadian biotech companies struggle with access to
capital and the lack of in-house production capabilities. On average it takes
7-10 years, and over $1 billion dollars to bring a product to market.
A major challenge in the Canadian biotechnology industry is that like
Dr. Banting and Dr. Best, Canadians are successful at reaching medical
discoveries in the laboratory but have less expertise when it comes to
translating those discoveries into globally available commercial products.
Canadian biotechnology companies often have to seek resources outside of
Canada in order to launch commercially. This was the case for Dr. Banting and
Dr. Best who were compelled to partner with a U.S. company that had the
capability to manufacture insulin on a global scale.
"The problem in Canada is that while exciting work on protein-based
therapeutics takes place in the lab, there are significant regulatory and
commercial hurdles to overcome to get the product approved for broad use in
the general population," said Mr. Wellner. "University scientists and emerging
biotech companies need access to expertise to properly formulate, purify,
manufacture and distribute the biological protein so that it can be used at
the patient level - this is where Therapure Biopharma will have a huge impact
Located in Mississauga, Ontario, Therapure Biopharma's unique and
flexible 130,000 square foot cGMP manufacturing facility will be completed at
the end of October, generating a significant number of high quality
value-added jobs for Ontarians.
Biotechnology In Canada
- Biotechnology is simply the use of living organisms or products to
modify human health.
- In contrast to traditional pharmaceuticals that are chemically based,
biotechnology products are created from biologically based raw
- There are currently 532 biotech companies in Canada representing a
$4.2 billion industry.
- Canadian biotech companies invest a total of $1.7 billion in research
About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that
develops, manufactures, purifies, and packages therapeutic proteins. Therapure
Biopharma acquired its Canadian built and conceived facility from Hemosol
Corporation, a specialist in therapies derived from hemoglobin, a blood
protein. Therapure Biopharma applies scientific, manufacturing, and downstream
purification expertise with an intimate understanding of advanced biology,
complex proteins, and regulatory processes to develop effective and innovative
solutions to advance products from discovery to market.
For more information, please visit: www.therapurebio.com.
For further information:
For further information: Media Contact: Tricia Soltys, Narrative
Advocacy Media, (416) 922-2211 x 3278, email@example.com